Is there a survival benefit of a robotic approach to pancreatoduodenectomy for pancreatic cancer?

作     者：Dyre Kleive Sheraz Yaqub Kjetil Søreide 

作者机构：Department of Hepato-Pancreato-Biliary SurgeryOslo University HospitalOsloNorway Institute of Clinical MedicineUniversity of OsloOsloNorway Department of Gastrointestinal SurgeryStavanger University HospitalStavangerNorway Department of Clinical MedicineUniversity of BergenBergenNorway 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2023年第12卷第1期

页      面：92-94页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Pancreatic cancer pancreatoduodenectomy robotic surgery survival propensity score 

摘      要：Pancreatic cancer has an overall poor prognosis,and only about 15%can be offered surgical *** systemic therapy can achieve median overall survival rates up to 54 months,as reported in the PRODIGE-24 trial,for those who complete resection,have good performance status,a low carbohydrate antigen(CA)19-9 value and complete adjuvant therapy(1).